Pre-symptomatic Alzheimer's trials expand amid 139M dementia projection

For biopharma, the report marks Alzheimer's as the next chronic disease frontier: amyloid-targeting drugs have already entered market, and trials in pre-symptomatic patients are testing prevention rather than palliation. A projected 139 million dementia cases by 2050 defines the market; the clinical question is whether treating before symptoms can bend the curve. Blood-based biomarkers could unlock a screening funnel that transforms Alzheimer's from a niche neurology market into a broad chronic-care indication.

The World Alzheimer Report 2026, released by Alzheimer's Disease International on 20 September 2026, marks a turning point: Alzheimer's disease is now beginning to be framed as a treatable and preventable condition rather than an unavoidable consequence of ageing. The report projects that the number of people living with dementia globally will surpass 139 million by 2050, making it one of the world's leading causes of death. That scale makes the report's clinical optimism both significant and urgent. For years, Alzheimer's drug development was dominated by repeated late-stage failures, leading to what New Zealand neurologist and Alzheimers NZ spokesperson Dr Campbell Le Heron calls a 'fairly nihilistic view' that the condition could not be changed. The report argues that this view is now outdated.

“

These drugs target and remove amyloid plaque, the protein buildup that accumulates in the brains of people with Alzheimer's years before symptoms appear.

The shift is rooted in two developments. First, disease-modifying therapies that slow progression have entered the market internationally over the past several years. These drugs target and remove amyloid plaque, the protein buildup that accumulates in the brains of people with Alzheimer's years before symptoms appear. Their approval has validated the amyloid hypothesis enough to shift clinical practice, even though their benefits are modest and limited to certain patient groups. Second, diagnostic innovation is accelerating. Blood-based tests are emerging as a less invasive, more scalable alternative to PET scans and cerebrospinal fluid analysis, potentially enabling earlier identification of people at risk. That matters because Le Heron and other researchers now believe the greatest opportunity may lie in treating people before they have symptoms.

The report highlights trials, some involving New Zealand, that are treating pre-symptomatic individuals to see whether cognitive impairment can be prevented. This represents a fundamental shift from reactive, late-stage intervention to proactive, early interception. The clinical community still does not know whether this preventive approach will work. Le Heron is careful to state that the field does not yet know if prevention is achievable, but the possibility is now considered real enough to demand health systems prepare for it. He emphasizes that if prevention trials succeed, countries will need to improve diagnostic pathways for people with cognitive impairment and identify at-risk individuals before irreversible damage accumulates.

For health systems, this has immediate operational implications. Treating Alzheimer's as a preventable condition means building capacity for biomarker testing, specialist assessment, MRI monitoring, and infusion delivery. The current global dementia care infrastructure is largely oriented around late-stage support and long-term care, not early detection and chronic disease management. A shift to early intervention could reduce long-term care costs, but it will require upfront investment in diagnostics and workforce training. The 139 million projection by 2050 provides a stark deadline: without scalable screening, the majority of people who could benefit from early treatment may never be identified until too late.

For the pharmaceutical and biotech sectors, the report reinforces Alzheimer's as one of the largest unmet medical needs and commercial opportunities. The market for disease-modifying therapies is still nascent, constrained by diagnostic bottlenecks, safety concerns such as amyloid-related imaging abnormalities, and payer skepticism about modest efficacy. However, the emergence of blood biomarkers and prevention trials could expand the addressable population dramatically. If pre-symptomatic treatment is shown to delay or prevent dementia, the commercial calculus shifts from treating a few million diagnosed patients to screening tens of millions of at-risk adults. That would make Alzheimer's resemble cardiovascular disease: a chronic condition managed over decades with biomarker-guided therapy.